

Publicaties betreffende BOOG studies

d.d. december 2018

Inhoud

BOOG 2001-01 / TEAM.....	2
BOOG 2001-02 / AMAROS	11
BOOG 2002-02 / HERTAX	12
BOOG 2002-04 / HERA.....	12
BOOG 2003-02 / CALOR	14
BOOG 2003-04 / BCP	15
BOOG 2004-01 / Young Boost (CKTO 2003-13)	16
BOOG 2004-02 / TBP	17
BOOG 2005-02 / MATADOR.....	18
BOOG 2005-03 / MINDACT	18
BOOG 2006-01 / DATA	20
BOOG 2006-02 / OMEGA	20
BOOG 2006-03 / SUPREMO	21
BOOG 2006-04 / TEAM-II	223
BOOG 2006-05 / IDEAL	24
BOOG 2006-06 / ATX.....	24
BOOG 2006-07 / MIRROR	25
BOOG 2007-01 / ALLTO	26
BOOG 2007-02 / INTENS	28
BOOG 2008- 01 / 2-2-6 G-CSF	28
BOOG 2008-02 / A6181099 (SUTENT)	29
BOOG 2008-03 / HAT	29
BOOG 2009-01 / IRMA.....	30
BOOG 2009-02 / SNARB	30
BOOG 2009-03 / DCIS	30
BOOG 2009-04 / Male Breast cancer	30
BOOG 2009-05 / BOLERO-2	31
BOOG 2010-01 / NEO-ZOTAC	32
BOOG 2010-02 / STOP & GO	35
BOOG 2010-03 / RAPCHEM.....	356
BOOG 2010-04 / D-CARE.....	36
BOOG 2010-05 / SUBMIT	36
BOOG 2012-01 / BALLET	37
BOOG 2012-02 / SafeHer	37
BOOG 2012-03 / TRAIN-2.....	38
BOOG 2013-03 / PERNETTA.....	38
BOOG 2013-04 / DIRECT	38
BOOG 2013-06 / BIOMARKER EVEROLIMUS	39
BOOG 2014-01 / MONALEESA-2.....	39
BOOG 2014-03 / OLYMPIA.....	40
BOOG 2014-04 / LORD.....	40
BOOG 2014-05 / INFLAME.....	40
BOOG 2015-02 / MONALEESA-3.....	41
BOOG 2017-03 / SONIA.....	41
BOOG 2018-01 / TRAIN-3.....	41
Patiëntenparticipatie	42

BOOG 2001-01 / TEAM

TEAM

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.

Bayani J, Yao CQ, Quintayo MA, Yan F, Haider S, D'Costa A, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Boutros PC, Bartlett JMS.
NPJ Breast Cancer. 2017 Feb 15;3:3.

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.

Engels CC, de Glas NA, Sajet A, Bastiaannet E, Smit VT, Kuppen PJ, Seynaeve C, van de Velde CJ, Liefers GJ.
Mol Oncol. 2016 Apr;10(4):509-16.

Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial.

Derkx MG, de Glas NA, Bastiaannet E, de Craen AJ, Portielje JE, van de Velde CJ, van Leeuwen FE, Liefers GJ.
Oncologist. 2016 Aug;21(8):946-53.

Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival.

Danny Houtsma, Stefanie de Groot, Tahar van der Straaten, Renee Baak-Pablo, Cock J.H. van der Velde, Henk-Jan Guchelaar, Hans Gelderblom
ASCO 2014

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW.
Arch Pathol Lab Med. 2016 Jan;140(1):66-74.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde CJH, Pan H, Peto R, Davies C, Gray R.
Lancet. 2015 Oct 3;386(10001):1341-52.

S4-06. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS et al.
(2015) SABCS

P2-08-29. Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial.

Bayani J et al.
(2015) SABCS

Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study

John MS Bartlett¹, Cassandra L Brookes², Fu J Yan¹, Mary Anne Quintayo¹, Jane Bayani¹, Jane Starczynski³, Cornelis JH van de Velde⁴, Annette Hasenburg⁵, Dirk G Kieback⁶, Christos Markopoulos⁷, Luc Dirix⁸, Caroline Seynaeve⁹ and Daniel W Rea²



SABCS 2014, publication number P4-11-05

PIK3CA Mutations Are Linked to PgR Expression: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) Pathology Study.

Sabine VS, Crozier C, Drake C, Piper T, van de Velde CJH, Hasenborg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Bartlett JMS

SABCS 2012

Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.

DBY Fontein, D Houtsma, ETM Hille, C Seynaeve, H Putter, E Meershoek-Klein Kranenborg, HJ Guchelaar, H Gelderblom, LY Dirix, R Paridaens, JMS Bartlett, JWR Nortier, CJH van de Velde, on behalf of the Dutch TEAM steering committee.

(2012) *Ann Oncol*, Aug 2 [Epub ahead of print]

Influence of semi-quantitative estrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – a TEAM study analysis.

W van de Water and DBY Fontein, JGH van Nes, JMS Bartlett, ETM Hille, H Putter, T Robson, GJ Liefers, RMH Roumen, C Seynaeve, LY Dirix, R Paridaens, E Meershoek-Klein Kranenborg, JWR Nortier, CJH van de Velde

(2012) *European Journal of Cancer*, accepted July 2012

Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

van de Water W, Markopoulos C, van de Velde CJH, Seynaeve C, Hasenborg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ETM, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE. JAMA.

(2012) *2012 Feb 8;307(6):590-7.*

Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.

van de Water W, Bastiaannet E, Hille ETM, Meershoek-Klein Kranenborg E, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJH.

(2012) *Oncologist*; 17(1):55-63. Epub 2011 Dec 30.

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors – a TEAM trial analysis.

Duveken BY Fontein, Peyman Hadji, Caroline Seynaeve, Annette Hasenborg, Robert Paridaens, Jean-Michel Vannetzel, Christos Markopoulos, Stephen E Jones, Daniel Rea, Cornelis JH van de Velde.

(2012) *Presentatie ESSO 2012, 19-21 september, Valencia*

Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition.

Bartlett AI, Starczynski J, Robson T, MacLellan A, Campbell FM, van de Velde CJH, Hasenborg A, Markopoulos C, Seynaeve C, Rea D, Bartlett JMS

(2011) *American Journal of Clinical Pathology* **136** (2): 266-274

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial.

Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, Grant M, Hasenborg A, Hille ETM, Kay C, Kieback DG, Putter H, Markopoulos C, Meershoek-Klein-Kranenborg E, Mallon EA, Dirix L, Seynaeve C, Rea D

(2011) *Journal of Clinical Oncology* **29** (12): 1531-1538

Efficacy of endocrine therapy regimens in major histological subtypes of breast cancer – TEAM study analysis.

Fontein DBY, van de Water W, Bartlett JMS, Liefers GJ, Markopoulos C, Seynaeve C, Meershoek-Klein-Kranenborg E, Rea D, Jones SE, Hille ETM, Putter H, Roumen RMH, Nortier JWR, van de Velde CJH
(2011) *Ejc Supplements*

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.

Hadj P, Asmar L, van Nes JGH, Menschik T, Hasenburg A, Kuck J, Nortier JWR, van de Velde CJH, Jones SE, Ziller M
(2011) *Journal of Cancer Research and Clinical Oncology* **137** (6): 1015-1025

Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis.

Hadj P, Asmar L, van Nes JG, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, Van der Velde C, Ziller M
(2011) *Breast* **20** S70

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.

Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y
(2011) *Annals of Oncology* **22** (8): 1777-1782

Age specific competing mortality in breast cancer patients – a TEAM study analysis.

Markopoulos C, van de Water W, Putter H, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, van de Velde CJH, Jones SE
(2011) *Ejc Supplements*

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

Van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ETM, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Burdett JMS, Jones SE
(2011) *Lancet* **377** (9762): 321-331

Specific Adverse Events and Outcome in Hormone Receptor Positive Breast Cancer Patients on Endocrine Therapy – a TEAM Study Analysis.

Van de Water W, Hille ETM, Hadji P, Markopoulos C, Seynaeve C, Hasenburg A, Dirix L, Rea D, Jones SE, van de Velde CJH
(2011) *Ejc Supplements*

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy.

Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y
(2010) *Oncology* **79** (5-6): 376-381

Is 5-50% of Amplified Cells a Suitable Cut Off To Define Heterogeneous Amplification of the HER2 Oncogene?

Bartlett AI, Starczynski J, Robson T, van de Velde CJH, Hasenburg A, Markopoulos C, Rea DW, Campbell FM, Bartlett JMS
(2010) *Cancer Res* **70** (24 Suppl)

Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study.

Bartlett JMS, Brookes CL, van de Velde CJH, Stocken D, Campbell FM, Hasenburg A, Kay C, Kieback D, Markopoulos C, Meershoek-Klein-Kranenborg E, Mallon EA, Dirix L, Robson T, Seynaeve C, Rea DW
(2010) *Cancer Res* **70** (24 Suppl)

Mammostrat® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study.

Bartlett JMS, Bloom KJ, Goldstein NS, van de Velde CJH, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Robson T, Seynaeve C, Rea DW
(2010) *Cancer Res* **70** (24 Suppl)

An Integration of Biological and Pathological Marker Panel in the TEAM Pathology Sub-Study: The Impact of Different Parameters on Risk Estimation of Relapse at Both 2.75 and 5 Years.

Bartlett JMS, Stocken D, van de Velde CJH, Brookes CL, Robson T, Hasenburg A, Hille ETM, Kieback D, Markopoulos C, Mallon EA, Dirix L, Campbell FM, Seynaeve C, Rea DW
(2010) *Cancer Res* **70** (24 Suppl)

A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors.

Bartlett JMS, Gustavson M, Stocken D, Rimm D, Christiansen J, van de Velde CJH, Hasenburg A, Kieback D, Putter H, Brookes C, Markopoulos C, Dirix L, Robson T, Seynaeve C, Dolled-Filhart M, Jones C, Graves L, McGuire J, Rea D
(2010) *Cancer Res* **70** (24 Suppl)

Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.

Dezentje VO, van Schaik RH, Vletter-Bogaartz JM, Wessels JA, Hille ETM, Seynaeve C, van de Velde CJH, Nortier JWR, Gelderblom H, Guchelaar HJ
(2010) *Journal of Clinical Oncology* **28** (15s)

Effects of Exemestane or Tamoxifen on Bone Health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial: A Meta-Analysis.

Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van de Velde CJH, Ziller M
(2010) *Cancer Res* **70** (24 Suppl)

Effects of Exemestane Or Tamoxifen on Bone Health Within the Tamoxifen Exemestane Adjuvant Multinational (Team) Trial: A Meta-Analysis.

Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van de Velde C, Ziller M
(2010) *Annals of Oncology* **21** 81-82

Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer.

Hasenburg A, van de Velde CJH, Seynaeve C, Rea DW, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Jones SE
(2010) *Ejc Supplements* **8** (3): 62

TEAM-studie: gelijkwaardige overleving door zowel monotherapie als sequentiële therapie.

Hille ETM
(2010) *Oncologie Up-to-Date* **1** (1): 3-4

Adjuvante endocriene therapie met exemestaan of de sequentie van tamoxifen, gevolgd door exemestaan bij postmenopauzale vrouwen met hormoongevoelige borstkanker.



Hille ETM, Seynaeve C, Nortier JWR, van de Velde CJH
(2010) *Nederlands Tijdschrift voor Oncologie* **7** (7): 304-309

The effect of exemestane and anastrozole on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: final results of 3 years after randomization of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.

Hozumi Y, Aihara T, Suemasu N, Takei H, Takehara M, Masuda N, Ohashi Y
(2010) *Ejc Supplements* **8** (3): 165

Competing Causes of Mortality vs. Breast Cancer Mortality at 5-Years among 9766 Postmenopausal Women with Hormone Receptor Positive Early Breast Cancer Treated on the TEAM Study of Adjuvant Hormonal Therapy.

Jones, S. E., Putter, H., Hasenburg, A., van de Velde, C. J. H., Rea, D. W., Vannetzel, J. M., Paridaens, R., Markopoulos, C., Hozumi, Y., and Seynaeve C.
(2010) *Cancer Res* **70**[24 Suppl]. 15-12-2010. Ref Type: Internet Communication

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy.

Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A
(2010) *Gynecologic Oncology* **119** (3): 500-505

Distant Recurrences at Median of 5-Years Among 9.779 Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Treated on the Team Trial of Adjuvant Endocrine Therapy.
Nortier H, Hille E, Rea D, Seynaeve C, Hasenburg A, Vannetzel J, Dirix L, Markopoulos C, van de Velde C, Jones S

(2010) *Annals of Oncology* **21** 78

Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, de Velde CJV, van Dam FS, Schagen SB
(2010) *Journal of Clinical Oncology* **28** (8): 1294-1300

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.

Schilder CMT, Seynaeve C, Linn SC, Boogerd W, Beex LVAM, Gundy CM, Nortier JWR, van de Velde CJH, Van Dam FSAM, Schagen SB
(2010) *Critical Reviews in Oncology Hematology* **76** (2): 133-141

The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer (BC) Patients; Exploratory Analysis from the TEAM Study.

Seynaeve C, Hille ETM, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier HWR, van Nes JGH, Dirix L, van de Velde CJH
(2010) *Cancer Res* **70** (24 Suppl)

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

Van de Velde CJH, Verma S, van Nes JGH, Masterman C, Pritchard KI
(2010) *Cancer Treatment Reviews* **36** (1): 54-62

Discontinuation during Tamoxifen in the Sequential Arm of the TEAM Trial of Adjuvant Endocrine Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer: The Effect of IES Results and Subsequent Therapy.

Van de Velde CJH, Hille ETM, Rea D, Seynaeve C, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Bartlett JMS, Putter H, Jones SE
(2010) *Cancer Res* **70** (24 Suppl):

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.

Van Nes JGH, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJH
(2010) *British Journal of Surgery* **97** (5): 671-679

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

Van Nes JGH, Seynaeve C, Maartense E, Roumen RMH, de Jong RS, Beex LVAM, Meershoek-Klein-Kranenborg E, Putter H, Nortier JWR, van de Velde CJH
(2010) *Annals of Oncology* **21** (5): 974-982

Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients.

Voskuil DW, van Nes JGH, Junggeburt JMC, van de Velde CJH, Van Leeuwen FE, De Haes JCJM
(2010) *Annals of Oncology* **21** (10): 2094-2101

The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy.

Bartlett JMS, Brookes C, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Quintayo MA, Lyttle N, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Meershoek-Klein-Kranenborg E, Paridaens R, Seynaeve C, Mallon EA, Rea DW
(2009) *Cancer Research* **69** (24): 503S

Estrogen and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational (TEAM) trial.

Bartlett JMS, Brookes CL, de Velde CJHV, Billingham LJ, Hasenberg A, Markopoulos C, Mallon EA, Paridaens R, Seynaeve C, Rea DW
(2009) *Ejc Supplements* **7** (2): 264

A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.

Bartlett JMS, Brookes CL, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback D, Markopoulos C, Meershoek-Klein-Kranenborg E, Mallon EA, Paridaens R, Robson T, Seynaeve C, van de Velde CJH, Rea D
(2009) *Cancer Research* **69** (2): 83S

Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.

Bartlett JMS, Rimm D, Brookes CL, Dolled-Filhart M, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Christiansen J, Gustavson M, Mallon EA, Kranenborg EMK, Paridaens R, Seynaeve C, Rea DW
(2009) *Cancer Research* **69** (24): 660S-661S

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer.

Dezentje VO, Guchelaar HJ, Nortier JWR, van de Velde CJH, Gelderblom H
(2009) *Clinical Cancer Research* **15** (1): 15-21

Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: The TEAM Trial Experience.



Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JMS
(2009) *Histopathology* **55** (5): 587-593

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A
(2009) *Breast* **18** (3): 159-164

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A
(2009) *Annals of Oncology* **20** (7): 1203-1209

Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.

Hadji P, Ziller M, Kieback D, Dornoff W, Tessen HW, Kuck J, Hasenburg A
(2009) *Cancer Research* **69** (2): 149S

Eerste resultaten van de TEAM-studie.

Hille ETM
(2009) *Oncology News International* **3** (1): 3-5

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, van de Velde CJH
(2009) *Cancer Research* **69** (2): 67S

Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.

Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H
(2009) *Annals of Oncology* **20** (1): 49-55

Aromatase inhibitors in the management of early breast cancer: The TEAM trial.

Markopoulos C
(2009) *Ejso* **35** (3): 333

Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

Rea D, Hasenburg A, Seynaeve C, Jones SE, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Asnar L, Urbanski R, van de Velde CH, Bartlett JMS, Smeets J, Kieback DG
(2009) *Cancer Research* **69** (24): 487S

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study.

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Huizenga HM, Nortier JW, van der Velder CJ, van Dam FS, Schagen SB
(2009) *Cancer Research* **69** (2): 146S

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological

TEAM-side study.

Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB
(2009) *Acta Oncologica* **48** (1): 76-85

Different effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the Dutch TEAM neuropsychological side study.

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB
(2009) *Ejc Supplements* **7** (2): 264

Tamoxifen and exemestane adjuvant multinational (TEAM) trial; findings from the Dutch/belgian subset.

Seynaeve C, van de Velde CJH, Maartense E, Roumen RMH, Nortier JWR, Hille ETM, van Nes JGH, Putter H, Paridaens R, Dirix LY
(2009) *Ejc Supplements* **7** (2): 300

Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.

Van de Velde C, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, Markopoulos C, Smeets J, Nortier JWR, Jones SE
(2009) *Ejc Supplements* **7** (3): 1

Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries.

Van Nes JGH, Seynaeve C, Jones S, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Markopoulos C, Meershoek-Klein-Kranenbarg E, van de Velde CJH
(2009) *Ejc Supplements* **7** (2): 301

Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.

Van Nes JGH, Papapoulos SE, Braun JJ, Dirix L, Putter H, Zwaan RE, Ballieux BEP, van Rongen I, van de Velde CJH, Seynaeve C, Nortier JWR
(2009) *Cancer Research* **69** (2): 152S-153S

Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.

Van Nes JGH, Voskuil DW, van Leeuwen RE, Junggeburt JMC, De Haes HCJM, van de Velde CJH
(2009) *Cancer Research* **69** (2): 69S

Physical activity to maintain quality of life in breast cancer survivors in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.

Voskuil DW, van Nes JG, Junggeburt JM, Van Leeuwen FE, van de Velde CJ, de Haes HC
(2009) *Cancer Research* **69** (2): 277S

TEAM trial and substudies confirm the efficacy and safety of exemestane in women with early hormone-sensitive breast cancer.

Jones S, Coombes RC, Schilder CTM, Voskuil DW, van Nes J, Hadji P, Bartlett J. (2008) *Highlights from 31st SABCS*

Clinical implications of CYP2D6 genotyping on tamoxifen treatment in breast cancer.

Dezentje VO, Nortier JWR, Guchelaar HJ, van de Velde CJH, Gelderblom H.
(2008) *Ejc Supplements* **6** (7): 56



Endometrial safety of cross-over treatment with tamoxifen followed by exemestane.

Kieback DG, Harbeck N, Bauer W, Hadji P, Weyers G, Hasenbusg A
(2008) *Ejc Supplements* **6** (7): 198

The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.

Ihara T, Hozumi Y, Suemasu K, Takei H, Takehara M, Osumi S, Saito T, Masuda N, Ohashi Y
(2007) *Breast Cancer Research and Treatment* **106** S114

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant Multicenter trial substudy.

Jones SE, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum JL, Brooks R, Hartung NL, Negron AG, Richards DA, Rivera R, Holmes FA, Chittoor S, Whittaker TL, Bordelon JH, Ketchel SJ, Davis JC, Illegbodu D, Kochis J, Asmar L
(2007) *Journal of Clinical Oncology* **25** (30): 4765-4771

The effect of exemestane, anastrozole and tamoxifen on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of NSAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.

Hozumi Y, Suemasu K, Takehara M, Takei H, Aihara T, Tamura M, Ohsumi S, Masuda N, Saito T, Mukai H, Ohashi Y
(2006) *Breast Cancer Research and Treatment* **100** S188

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study.

Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H
(2005) *Breast Cancer Research and Treatment* **93** (1): 61-66

The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study.

Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Papadiamantis J, Bafaloukos D, Misitzis J, Michailidou A, Gogas H
(2004) *Journal of Clinical Oncology* **22** (14): 76S

The effect of exemestane (Aromasin (R)) on the lipidemic profile of breast cancer patients: preliminary results of the TEAM trial Greek sub-study.

Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Bafaloukos D, Papadiamantis J, Misitzis J
(2003) *Breast Cancer Research and Treatment* **82** S105

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.

Engels CC, Charehbili A, van de Velde CJH, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ.
Breast Cancer Res Treat. 2015 Feb;149(3):587-96.

Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.

Fontein DB, Klinten Grand M, Nortier JW, Seynaeve C, Meershoek-Klein Kranenborg E, Dirix LY, van de Velde CJH, Putter H.
Ann Oncol. 2015 Jun;26(6):1254-62.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).

Eur J Cancer. 2017 Jul;79:129-138

Adjuvant tamoxifen and exemestane in postmenopausal early breast cancer: ten-year analysis of the TEAM trial.

Derkx MGM, Blok EJ, Seynaeve C, Nortier JWR, Meershoek-Klein Kranenborg E, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Smeets J, Dirix LY, Paridaens R, van de Velde CJH. *Lancet Oncology. 2017, Jul 18 on-line*

BOOG 2001-02 / AMAROS

10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node

EJT Rutgers et al,
SABCS 2018 oral presentation

Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome.

Donker M, Straver ME, van Tienhoven G, van de Velde CJ, Mansel RE, Litière S, Werutsky G, Duez NJ, Orzalesi L, Bouma WH, van der Mijle H, Nieuwenhuijzen GA, Veltkamp SC, Helen Westenberg A, Rutgers EJ.

Eur J Cancer. 2013 Jun;49(9):2093-100.

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023)

E. J. Rutgers, M. Donker, M. E. Straver, Ph. Meijnen, C. J. H. van de Velde, R. E. Mansel, H. Westenberg, L. Orzalesi, W.H. Bouma, H. van der Mijle, G. A. P. Nieuwenhuijzen, S. C. Veltkamp, L. Slaets, C.G. M. Messina, N. J. Duez, C. Hurkmans, J. Bogaerts, and G. van Tienhoven
Oral presentation **ASCO Abstract # LBA1001**

Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.

Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, Rutgers EJ.
Ann Surg Oncol. 2010 Jul;17(7):1854-61.

Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.

Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijl J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ.
J Clin Oncol. 2010 Feb 10;28(5):731-7.

Analyses met betrekking tot de technische aspecten, gebaseerd op de eerste 2000 patiënten zijn (met toestemming van de IDMC)

ASCO Breast Cancer Symposium (Washington DC, september 2008) en 31st San Antonio Breast Cancer Symposium in december 2008.

Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run.

Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G; EORTC Breast Cancer Cooperative Group; Radiotherapy Cooperative Group.

Radiother Oncol. 2003 Sep;68(3):233-40.

BOOG 2002-02 / HERTAX

Randomized phase II study comparing efficacy and safety of combination therapy trastuzumab and docetaxel versus sequential therapy of trastuzumab followed by docetaxel alone at progression as first line chemotherapy in patients with HER2-positive metastatic breast cancer: HERTAX trial.

P. Hamberg, M. M.E.M. Bos, H.J.J. Braun, J.M.L. Stouthard, G. A. van Deijk, F. L.G. Erdkamp, I.N. van der Stelt-Frisken, M. Bontenbal, G.J. M. Creemers, J.E.A. Portielje, J.F.M. Pruijt, O.J.L. Loosveld, W.M. Smit, E.W. Muller, P. I.M. Schmitz, C. Seynaeve, J.G.M. Klijn
Clinical Breast Cancer April 2011 p 103-113

Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study).

M. Bontenbal, C. Seynaeve, J. Stouthard, M. Bos, H. Braun, F. Erdkamp, G. van Deijk, P. Schmitz, I. van der Stelt-Frisken, P. Hamberg, J. Klijn

J Clin Oncol 26: 2008 (May 20 suppl; abstr 1014) Oral presentation

Sequential Rx effective, less toxic in metastatic breast cancer;
Oncology News International feb'08

Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (HERTAX).

P Hamberg, JML Stouthard, MM Bos, HJ Braun, F Erdkamp, G van Deijk, M Bontenbal, RM Vervloet, PIM Schmitz, C Seynaeve, JGM Klijn

Breast Cancer Research and Treatment, Vol. 106, Supplement 1, 2007; Abstract 1077

BOOG 2002-04 / HERA

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086.

Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J;

Lancet 382:1021-1028, 2013. (IBCSG 28-02) (Journal impact factor 39.060).

Three HERA abstracts were presented at SABCS 2011 (manuscripts under review):

1. Trastuzumab does not increase the incidence of central nervous system (CNS) relapses in HER2 positive early breast cancer: the HERA trial experience

2. Pregnancy during and following adjuvant trastuzumab in patients with HER2-positive breast cancer: An analysis from the HERA trial

3. The magnitude of trastuzumab benefit in HER2-positive (HER2+) lobular breast carcinoma (BC): Results from the HERA Trial

One publication:

Pregnancy during and following adjuvant trastuzumab in patients with HER2-positive breast cancer: An analysis from the HERA trial (BIG 1-01), Breast Cancer Res Treat



Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.

Younis T, Skedgel C.

Pharmacoeconomics. 2011 May 1;29(5):361-5. doi: 10.2165/11588350-00000000-00000. No abstract available.

HERA crosses over.

Joensuu H.

Lancet Oncol. 2011 Mar;12(3):203-4. Epub 2011 Feb 25. No abstract available.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team.

Lancet Oncol. 2011 Mar;12(3):236-44. Epub 2011 Feb 25.

The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial

Partridge AH, Gelber S, Piccart M, Focant F, Scullion M, Winer E, Gelber R, on Behalf of the HERA Trial Study Team.

Cancer Res; 70(24 Suppl) Dec 15, 2010; P4-09-12

Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience

Zabaglo L, Stoss O, Rueschoff J, Zielinski D, Salter J, Bradbury I, Arfi M, Dafni O, Procter M, Dowsett M, HERA Trial Study Team

Cancer Res; 70(24 Suppl) Dec 15, 2010; PG10-01

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.

J Clin Oncol. 2010 Jul 20;28(21):3422-8. Epub 2010 Jun 7.

The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.

Skedgel C, Rayson D, Younis T.

Value Health. 2009 Jul-Aug;12(5):641-8.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Dowsett M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B.

J Clin Oncol. 2009 Jun 20;27(18):2962-9. Epub 2009 Apr 13.

When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.

De Rossi C, Brunello A, Jirillo G, Jirillo A.

Immunopharmacol Immunotoxicol. 2009 Mar;31(1):30-1. Review.

When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.

De Rossi C, Brunello A, Jirillo G, Jirillo A.

Immunopharmacol Immunotoxicol. 2009;31(1):1-4.



Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.

Ann Oncol. 2008 ;18:909-916.

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.

Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D.

Ann Oncol. 2007 Sep;18(9):1493-9.

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.

Breast Cancer Res Treat. 2008 Jun;109(3):559-66. Epub 2007 Jul 28.

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.

J Clin Oncol. 2007 Sep 1;25(25):3859-65. Epub 2007 Jul 23.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart, for the HERA study team

The Lancet, Vol 369 (9555):29-36, January 6, 2007

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.

NEJM 2005; 353:1659- 1672.

BOOG 2003-02 / CALOR

The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence.

Chan N, Toppmeyer DL.

J Clin Oncol. 2018 Apr 10, doi: 10.1200/JCO.2017.77.4877.

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Paterson AHG, Rimawi MF, Láng I, Baena-Cañada JM, Thürlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S;

J Clin Oncol. 2018 Feb 14 doi: 10.1200/JCO.2017.76.5719.

Chemotherapy (CT) for Isolated Locoregional Recurrence (ILRR) of Breast Cancer in ER-Positive (ER+) and ER-Negative (ER-) Cohorts: Final Analysis of the CALOR Trial

International Breast Cancer Study Group, Breast International Group, NRG Oncology (NSABP Legacy)

Irene Wapnir, Karen N. Price, Stewart J. Anderson, Andre Robidoux, Miguel Martín, J. W. R. Nortier, Alexander H. G. Paterson, Mothaffar F. Rimawi,

István Láng, José Manuel Baena Cañada, Beat J. K. Thürlimann, Eleftherios P. Mamounas, Charles E. Geyer Jr., Shari Gelber, Alan S. Coates, Richard D. Gelber, Priya Rastogi, Meredith M. Regan, Norman Wolmark, Stefan Aebi

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial

Irene L. Wapnir, MD1, Shari Gelber, MS2, Stewart J. Anderson, PhD3, Eleftherios P. Mamounas, MD4, André Robidoux, MD5, Miguel Martín, MD6, Johan W. R. Nortier, MD7, Charles E. Geyer Jr, MD8, Alexander H. G. Paterson, MD9, István Láng, MD10, Karen N. Price, BS2, Alan S. Coates, MD11, Richard D. Gelber, PhD12, Priya Rastogi, MD13, Meredith M. Regan, ScD14, Norman Wolmark, MD15, Stefan Aebi, MD16, and On behalf of CALOR trial investigators.

Annals of Surgical Oncology – 2017

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

Dr Stefan Aebi, Shari Gelber , Stewart J Anderson, István Láng , André Robidoux , Miguel Martín , Johan W R Nortier , Alexander H G Paterson , Mothaffar F Rimawi , José Manuel Baena Cañada , Beat Thürlimann MD c o, Elizabeth Murray MD p, Eleftherios P Mamounas MD q, Charles E Geyer MD r, Karen N Price , Alan S Coates , t, Richard D Gelber , Priya Rastogi , Norman Wolmark , Irene L Wapnir
The Lancet Oncology, Volume 15, Issue 2, Pages 156 - 163, February 2014

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)

Aebi S, Gelber S, Láng I, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Mamounas EP, Geyer, Jr. CE, Maibach R, Gelber RD, Wolmark N, Wapnir IL. International Breast Cancer Study Group, Bern, Switzerland; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Breast International Group, Brussels, Belgium
SABCS 2012

Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer) Trial IBCSG 27-02, NSABP B-37, BIG 1-02

Irene L. Wapnir, Shari Gelber, István Láng, Stewart J. Anderson, André Robidoux, Miguel Martín, Johan W.R. Nortier, Eleftherios P. Mamounas, Charles E. Geyer, Jr., Rudolf Maibach, Richard D. Gelber, Norman Wolmark, Stefan Aebi

Accepted SABCS 2012

Progress on BIG 1-02/IBCSG 27-02/ NSABP B-37, A Prospective Randomized Trial of Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer

Irene L. Wapnir, Stefan Aebi, Shari Gelber, Charles E. Geyer, Stewart Anderson, István Láng, Andre Robidoux A, Mamounas EP, Wolmark N
Ann Surg Oncol 15:3227-3231, 2008

A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N.
Clinical Breast Cancer 8:287-292, 2008.

BOOG 2003-04 / BCP

Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.

Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S.
J Clin Oncol. 2013; 10;31:2532-9



Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial

Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calsteren B, Loibl S
Cancer Res; 72(24 Suppl) Dec 15, 2012; 514 s (P6-07-05)

Treatment of breast cancer during pregnancy: an observational study.

S. Loibl, S. N. Han, G. Von Minckwitz, M. Bontenbal, A. Ring, J. Giermek, T. Fehm, K. Vanalsteren, S. Linn, B. Schlehe, et al.
The Lancet Oncology. 2012 Sept; 13(9): pag 887-896

Patients with Breast Cancer during Pregnancy – Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03).

Loibl S, Amant F, Kaufmann M, Ring A, Sileny H, Giermek J, Fehm T, Bontenbal M, Heinrichs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G.
Cancer Res; 70(24 Suppl) Dec 15, 2010; S6-2

Breast cancer in pregnancy: recommendations of an international consensus meeting.

Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A.
Eur J Cancer. 2010 Dec;46(18):3158-68.

Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03)

Loibl S, Bontenbal M, Ring A, UFK FFM NN, Crivellari D, Fehm T, Heinrichs M, Lenhard M, Mehta K, von Minckwitz G
Abstract EBCC 2010

BOOG 2004-01 / Young Boost (CKTO 2003-13)

Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial.

Brouwers PJAM, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJEE, Schinagl DAX, Westenberg AH, Poortmans P, Boersma LJ; Young Boost Trial research group.

Radiother Oncol. 2018 Sep;128(3):434-441. doi: 10.1016/j.radonc.2018.06.020. Epub 2018 Jul 3.

Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial.

Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJ, Schinagl DA, Westenberg AH, Poortmans P, Boersma LJ; **Young Boost** Trial research group.

Radiother Oncol. 2016 Jul;120(1):107-13. doi: 10.1016/j.radonc.2016.04.017. Epub 2016 May 28.

The influence of the boost dose on cosmetic outcome after breast conserving therapy: results of the Young Boost Trial

P.J.A.M. Brouwers^a, E van Werkhoven^b, B. Hanbeukers^a, J. van Loon^a, J.W. Leer^c, P.M. Poortmans^c, H.Bartelink^b and L.J. Boersma^a on behalf of the Young Boost Trial research group.
ESTRO 2015, Barcelona.

Phase III trial of low vs high radiation boost in young breast cancer patients

Boersma L., Bartelink H., Poortmans P.M., Leer J.W.
V&VN-oncologica nummer 01.2011

Multi-institutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines.



van Mourik AM, Elkhuzen PH, Minkema D, Duppen JC; Dutch Young Boost Study Group, van Vliet-Vroegindeweij C.
Radiother Oncol. 2010 Mar;94(3):286-91. Epub 2010 Mar 2.

The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment.

Al Uwini S, Antonini N, Poortmans PM, Boersma L, Hurkmans C, Leer JW, Horiot JC, Struikmans H, Bartelink H.
Radiother Oncol. 2009 Oct;93(1):87-93. Epub 2009 Jun 8.

BOOG 2004-02 / TBP

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; On behalf of the GBG 26/BIG 03-05 study group and participating investigators.
Eur J Cancer. 2011 Jul 7

Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment.

von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh F, Baumann K, Bischoff J, Harbeck N, Lück H-J, Maass N, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S.

Cancer Res; 70(24 Suppl) Dec 15, 2010;P6-14-05

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gunter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolai Maass, Tanja Cufer, Felix E. de Jongh, Eduard Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer, Klaus H. Baumann, Michael R. Clemens, Ralph Duerr, Christoph Uleer, Michael Andersson, Robert C. Stein, Valentina Nekljudova, and Sibylle Loibl

JCO Vol 27, Nr 12, April 20, 2009

Continuing Trastuzumab Beyond Progression

Jahanzeb M, Division of Hematology Oncology, College of Medicine, University of Tennessee, Memphis, TN, and Aptium Oncology, Lynn Cancer Institute, West Campus, Boca Raton, FL
JCO Vol 27, Nr 12, April 20, 2009

Media Release: Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression (results of a multicenter, randomized phase III study comparing capecitabine alone versus in combination with trastuzumab in patients with HER2-positive metastatic breast cancer and progression after previous treatment with trastuzumab)

German Breast Group, September 14, 2008

Continuering van combinatietherapie bij behandeling van uitgezaaide borstkanker remt ziekteprogressie

Persbericht 9 juni 2008

Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26 / BIG 3-05)

Von Minckwitz G, Zielinski C, Maartense E, du Bois A, Schmidt M, Maass N, Cufer T, De Jongh FE, Andersson M, Stein R, Kaufmann M, Nekljudova V, Loibl S

Presented at the 44th ASCO Annual Meeting 2008, May 30-June 3, Chicago, Illinois , USA

Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer –the TBP study (GBG 26/BIG 3-05).

Von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S
Breast Cancer Research and Treatment, Vol. 106, Supplement 1, 2007; ASCO Abstract 4056

BOOG 2005-02 / MATADOR
Abstract ESMO 2018

Manuscript submitted

Abstract SABCS 2016

GSTP1 polymorphism is associated with chemotherapy-induced neuropathy

N.C.Miltenburg, M.Opdam, M.Winter, M.van Geer, H.M.Oosterkamp, W.Boogerd en S.C.Linn
SABCS 2012

**De MATADOR-studie: multicenter fase-III-onderzoek naar chemotherapie op maat bij het
mammacarcinoom.**

Linn SC, Helgason HH, Oosterkamp HM
Ned Tijdschr Oncol 2005;2:193-8.

BOOG 2005-03 / MINDACT

**Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk
patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.**

Aalders KC, Kuijper A, Straver ME, Slaets L, Litiere S, Viale G, Vant Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart-Gebhart M, Cardoso F, Rutgers EJ
Eur J Cancer. 2017 Jul doi: 10.1016/j.ejca.2017.03.034. Epub 2017 May 3.

Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
Ann Oncol. 2014 Apr;25(4):816-23. doi: 10.1093/annonc/mdu026.

Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.

Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling: logistics pilot study preceding the MINDACT trial.
Eur J Cancer. 2009 May;45(7):1201-8. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial.
J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium. The MINDACT trial: the first prospective clinical validation of a genomic tool.
Mol Oncol. 2007 Dec;1(3):246-51. doi: 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.

N Engl J Med. 2016 Aug 25;375(8):717-29.

Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
 Giuseppe Viale¹, Leen Slaets², Femke A de Snoo³, Jan Bogaerts², Laura J van 't Veer⁴, Emiel J Rutgers⁵, Martine J Piccart-Gebhart⁶, Jeroen van den Akker³, Lisette Stork-Sloots³, Leila Russo¹, Patrizia Dell'Orto¹, Fatima Cardoso⁷

SABCS 2014 publication number: P4-11-08

Are all small tumors low risk? Characterization of small invasive node negative breast cancers (BC) enrolled in the EORTC 10041/BIG 3-04 (MINDACT) trial

Konstantinos Tryfonidis¹, Leen Slaets², Giuseppe Viale³, Femke Snoo⁴, Laura Van't Veer⁵, Emiel Rutgers⁶, Martine Piccart⁷, Jan Bogaerts² and Fatima Cardoso⁸.

SABCS 2014, publication number: P2-03-01

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.

Rutgers E¹, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F.
Eur J Cancer. 2011 Dec;47(18):2742-9.

The EORTC 10041/BIG 03-04 MINDACT (Microarray in Node Negative Disease may Avoid ChemoTherapy) Trial: Patients' baseline Characteristics and Logistics Aspects After a Successfull Accrual

Piccart M, Bogaerts J, Cardoso F, Werutsky G, Delaloge S, Van 't Veer L, Rubio I, Moulin C, Engelen K, Viale G, Thompson AM, Passalacqua, Nitz U, Vuylsteke P, Pierga JY, Rutgers E
Abstract ESMO 2011

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Mook S, Schmidt MK, Viale G, Pruner I, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.
Breast Cancer Res Treat. 2009 Jul;116(2):295-302.

Clinical application of the 70-gene profile: the MINDACT trial.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.
J Clin Oncol. 2008 Feb 10;26(5):729-35

MINDACT Microarray in Node Negative Disease may Avoid ChemoTherapy. Een unieke studie voor borstkankerpatiënten en onderzoeker.

I. Eekhout, S. Mook, E.Th Rutgers
Nederlands Tijdschrift voor Oncologie, 2008

The MINDACT trial: the first prospective clinical validation of a genomic tool

Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium.
Mol Oncol. 2007 Dec;1(3):246-51.

Individualization of Therapy Using Mammaprint: from Development to the MINDACT trial

Stella Mook, Laura Van't Veer, Emiel Rutgers, Martine Piccart-Gebhart and Fatima Cardoso
CANCER GENOMICS & PROTEOMICS 4: 147-156 (2007)

MINDACT Trial: A prospective trial to validate the Amsterdam signature

Rutgers E.
Breast International Group 1 ASCO 43rd Annual meeting 2007 - Educational Book: 40-44,2007.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.
Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.
Nat Clin Pract Oncol. 2006 Oct;3(10):540-51.

BOOG 2006-01 / DATA

No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

I.E. van Hellmond et al,
SABCS 2018 abstract P4-14-11

BOOG 2006-02 / OMEGA

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

C. H. Smorenburg; S. M. de Groot; A. E. van Leeuwen-Stok; M. E. Hamaker; A. N. Wymenga; H. de Graaf; F. E. de Jongh; J. J. Braun; M. Los; E. Maartense; H. van Tinteren; J. W. R. Nortier; C. Seynaeve
Annals of Oncology 2014; doi: 10.1093/annonc/mdt588

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

M.E. Hamaker, C. Seynaeve, A.N.M. Wymenga, H. van Tinteren, J.W.R. Nortier, E. Maartense, H. de Graaf, F.E. de Jongh, J.J. Braun, M. Los, J.G. Schrama, A.E. van Leeuwen-Stok, S.M. de Groot, C.H. Smorenburg.

Breast 2013;xx: 1-7

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study

M.E. Hamaker, C. Seynaeve, J.W.R. Nortier, M. Wymenga, E. Maartense, E. Boven, A.E. van Leeuwen-Stok, S.E. de Rooij, B.C. van Munster, C.H. Smorenburg

Breast 2013;22:556-9.

First-line chemotherapy with pegylated liposomal doxorubicin (PEGdodoxo) versus capecitabine (Cape) in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)

C.H. Smorenburg, C. Seynaeve, A.N.M. Wymenga, E. Maartense, H. de Graaf, F.E. de Jongh, J.J. Braun, M. Los, J.G. Schrama, J.E.A. Portielje, M. Hamaker, H. van Tinteren, S.M. de Groot, A.E. van Leeuwen-Stok, J.W.R. Nortier

Poster SABCS 2012

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review

Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC.

Lancet Oncol 2012; Vol 13: Issue 11, e437-44.

Resultaten van de klinische studie gepresenteerd op een congres/symposium:

Baseline comprehensive geriatric assessment predicts for toxicity of single agent chemotherapy in elderly metastatic breast cancer patients: results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

M.E. Hamaker, C. Seynaeve, A.N.M. Wymenga, H. van Tinteren, J.W.R. Nortier, E. Maartense, S.M. de Groot, C.H. Smorenburg

ASCO 2012 accepted as poster presentation

Toxicities and feasibility associated with PEG doxo versus Capecitabine (Cape) as first line chemotherapy in elderly metastatic breast cancer patients (OMEGA trial)

C. Seynaeve, H. van Tinteren, ANM Wymenga, JWR Nortier, E. Maartense, FE de Jongh, H. de Graaf, SM de Groot, JJ Braun, CH Smorenburg

EBCC-8 2012 accepted as poster presentation

Reasons for low accrual of elderly patients with metastatic breast cancer in the OMEGA study of the Dutch Breast cancer Trialists' Group (BOOG).

ME Hamaker, C Seynaeve, ANM Wymenga, JWR Nortier, E Maartense, FE de Jongh, H de Graaf, JJ Braun, SM de Groot, AE van Leeuwen-Stok, CH Smorenburg

SIOG November 2011 accepted as oral presentation

De OMEGA studie. Een gerandomiseerde fase III-studie betreffende eerstelijnschemotherapie met gepegyleerd liposomaal doxorubicine of capecitabine bij patienten vanaf 65 jaar met gemitastaseerd mammaarcinoom, inclusief geriatrische evaluatie.

CH Smorenburg, ANM Wymenga, E Maartense, JWR Nortier, C Seynaeve.

Ned Tijdschrift Oncol 2009;6:275-8

Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.

Hamberg P, Verweij J, Seynaeve C.

Eur J Cancer. 2007 Jul;43(10):1514-28.

BOOG 2006-03 / SUPREMO

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

G.Velikova, L.J. Williams, S.Willis, J.M. Dixon, J. Lancaster, M. Hatton, et al

Lancet Oncology, V 19, issue 11, p1516-1529, November 01, 2018

Pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

Thomas JS, Hanby AM, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron DA, Bartlett JM, Piper T, Cunningham C, Canney P, Kunkler IH; SUPREMO Trial Management Group.
Breast Cancer Res Treat. 2017 May;163(1):63-69.

European interpretation of North American post mastectomy radiotherapy guideline update.

Kunkler IH, Dixon JM, MacLennan M, Russell NS.
Eur J Surg Oncol 2017;43(10):1805-7.

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

Thomas JS, Hanby AM, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron DA, Bartlett JM, Piper T, Cunningham C, Canney P, Kunkler IH; SUPREMO Trial Management Group.
Breast Cancer Res Treat. 2017 May;163(1):63-69. doi: 10.1007/s10549-017-4145-4. Epub 2017 Feb 11.

The SUPREMO Trial – Pathology quality assurance of a large phase III randomised international clinical trial.

Jeremy Thomas, Andrew Hanby, Nicola Russell, Geertjan van Tienhoven, Kathleen Riddle, David Cameron, John Bartlett, Tammy Piper, Carrie Cunningham, Peter Canney, Ian Kunkler.
EBCC-10 2016 poster presentation.

Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria.

Russell NS, Kunkler IH, van Tienhoven G.
Ann Oncol. 2015 Jun;26(6):1043-4.

Post-mastectomy radiotherapy- will SUPREMO end the debate? Russell NS, Kunkler I, van Tienhoven G, Canney PA, Thomas J, Bartlett, J van de Vijver MJ, Belkacemi Y, Yarnold JR, Barrett-lee PJ. J.
Clin Oncol 2009; 27 (6): 996-7.

SUPREMO trial management group. Elucidating the role of chest wall irradiation in "intermediate-risk" breast cancer: the MRC/EORTC SUPREMO trial.

I.H. Kunkler, P. Canney, G. Van Tienhoven, N.S. Russell on behalf of the MRC/EORTC (BIG 2-04)
Clin Oncol 20: 31-34, 2008.

BOOG 2006-04 / TEAM-II

TEAM IIA

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

Fontein DB, Charehbili A, Nortier JW, Putter H, Meershoek-Klein Kranenborg E, Kroep JR, Linn SC, van de Velde CJH.

Eur J Surg Oncol. 2017 Apr;43(4):619-624.

ER pathway activity as a predictive biomarker for neoadjuvant endocrine therapy. Blok et al.
SABCS 2016 P3-07-65.

Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer. Blok et al.
SABCS 2016 P6-01-05.



BOOG 2006-04TEAM IIB

Abstract SABCS 2016 poster discussion

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.
Lancet. 2015 Oct 3;386(10001):1353-61.

Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - a phase II trial

D.B.Y.Fontein, C.J.H.van de Velde, A.Charehbili, W.M.Meershoek-Klein Kranenbarg, J.W.R.Nortier, J.R.Kroep, H.Putter, G.J.Liefers, S.C.Linn, Y. van Riet, G. Nieuwenhuijzen, B. de Valk, J.M. Meerumterwogt, G. Algie
Eur J Cancer 2014

BOOG 2006-05 / IDEAL

EDITORIAL

Searching for the IDEAL Duration of Adjuvant Endocrine Therapy

Rachel L. Yung, Nancy E. Davidson
JNCI J Natl Cancer Inst (2018)

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Erik J. Blok, Judith R. Kroep, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Hein Putter, Joan van den Bosch, Eduard Maartense, A. Elise van Leeuwen-Stok, Gerrit-Jan Liefers, Johan W.R. Nortier, Emiel J.Th. Rutgers, Cornelis J.H. van de Velde; on behalf of the IDEAL Study Group
JNCI J Natl Cancer Inst (2018)

Optimal duration of extended adjuvant endocrine therapy for early breast cancer.

Blok E, Kroep J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok E, Liefers G, Nortier J, Rutgers E, van de Velde CJH, on behalf of the IDEAL Study Group
J Natl Cancer Inst. 2017, Mid July on-line

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

van de Velde CJH, Blok E, Meershoek-Klein Kranenbarg E, Putter H, van den Bosch J, Maartense E, Duijm-de Carpentier M, van Leeuwen-Stok E, Liefers G, Nortier J, Rutgers E, Kroep J
ECCO abstract January 2017

Abstracts SABCS 2016 oral presentation and poster

High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.

Fontein DBY, Nortier JWR, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, Maartense E, Rutgers EJTh, van de Velde CJH, Eur J (2012) *Surg Oncol.* 2012 Feb;38(2):110-7. *Epub 2011 Dec 14.*

High Rates of Nonadherence to Aromatase Inhibitors in the Extended Adjuvant Setting

DBY Fontein, JWR Nortier, H Putter, E Meershoek-Klein Kranenbarg, EJTh Rutgers, CJH van de Velde
Poster #: 5.162 op ECCO 16, 24-27 September 2011, Stockholm

Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.

Kool M, Fontein DB, Meershoek-Klein Kranenborg E, Nortier JW, Rutgers EJ, Marang-van de Mheen PJ, van de Velde CJH.
Breast. 2015 Jun;24(3):224-9.

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.

Blok EJ, Derkx MG, van der Hoeven JJ, van de Velde CJH, Kroep JR.
Cancer Treat Rev. 2015 Mar;41(3):271-6.

BOOG 2006-06 / ATX

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.

Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E.
Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.326.

The role of pharmacogenetics in capecitabine efficacy and toxicity.

Lam SW, Guchelaar HJ, Boven E.
Cancer Treat Rev. 2016 Aug 10;50:9-22. doi: 10.1016/j.ctrv.2016.08.001. Review.

Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.

Lam SW, Nota NM, Jager A, Bos MM, van den Bosch J, van der Velden AM, Portielje JE, Honkoop AH, van Tinteren H, Boven E; ATX Trial Team..
Clin Cancer Res. 2016 Apr 1;22(7):1611-20. doi: 10.1158/1078-0432.CCR-15-1005.

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.

Frederiks CN, Lam SW, Guchelaar HJ, Boven E.
Cancer Treat Rev. 2015 Dec;41(10):935-50. doi: 10.1016/j.ctrv.2015.10.010. Review.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.
Eur J Cancer. 2014 Dec;50(18):3077-88.

Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

Siu W¹, Nienke M², Nota¹, Steffen M³, de Groot², Agnes Jager³, Monique MEM⁴, Bos⁴, Sabine C Linn⁵, Joan van den Bosch⁶, Hans J Braun⁷, Ankje MT van der Velden⁸, Maartje Los⁹, Johanneke EA Portielje¹⁰, Judith R Kroep¹¹, Aafke H Honkoop¹², Carolien H Smorenburg¹³, Bea Tanis¹⁴, Johanna MGH van Riel¹⁵, Jetske M Meerum Terwogt¹⁶, Marien O den Boer¹⁷, Joep Douma¹⁸, Frank Jeurissen¹⁹, Johan Berends²⁰, Harm van Tinteren⁵ and Epie Boven¹.

SABCS 2014, publication number P3-06-09

Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients

Siu W Lam¹, Charlotte N Frederiks¹, Tahar van der Straaten², Steffen M de Groot³, Agnes Jager⁴, Monique MEM Bos⁵, Sabine C Linn⁶, Joan van den Bosch⁷, Hans J Braun⁸, Ankje MT van der Velden⁹, Maartje Los¹⁰, Johanneke EA Portielje¹¹, Judith R Kroep², Aafke H Honkoop¹², Carolien H Smorenburg¹³, Bea Tanis¹⁴, Johanna MGH van Riel¹⁵, Jetske M Meerum Terwogt¹⁶, Marien O den Boer¹⁷, Joep Douma¹⁸, Frank Jeurissen¹⁹, Johan Berends²⁰, Henk-Jan Guchelaar² and Epie Boven¹.
SABCS 2014 publication number P6-08-09

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven, on behalf of the Dutch Breast Cancer Research Group (BOOG).

Eur J Cancer 2014 (conditionally accepted)

Plasma VEGF-A, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

S.W. Lam, S.M. de Groot, A.H. Honkoop, N.M. Nota, A. Jager, A.W.T van der Velden, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, R.R. de Haas, C.H. Smorenburg, H. de Graaf, J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren and E. Boven.

J Clin Oncol 31, 2013 (suppl; abstr 1072)

Plasma VEGF-A, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

S.W. Lam, S.M. de Groot, A.H. Honkoop, N.M. Nota, A. Jager, A.W.T van der Velden, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, R.R. de Haas, C.H. Smorenburg, H. de Graaf J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren and E. Boven.

Abstract ASCO 2013

Combination of paclitaxel and bevacizumab without or with capecitabine as first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): first results from a randomized, multicenter, open-label, phase II study of the Dutch Breast Cancer Trialists' Group (BOOG) (abstract)

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.W.R. Nortier, J.J. Braun, H. de Graaf, J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren, E. Boven, *SABCS 2011*

BOOG onderzoekt combinatie bevacizumab met chemotherapie bij mammaarcinoom

E. Boven, A.H. Honkoop, H. van Tinteren C.L. van der Wilt, A.E. van Leeuwen-Stok
NvMO tijdschrift, 2008

ATX-studie: een multicentrische gerandomiseerde fase II BOOG-studie naar de behandeling van HER2-negatief gemitastaseerd mammaarcinoom.

E. Boven, A.H. Honkoop, C.L. van der Wilt, A.E. van Leeuwen-Stok
Ned. Tijdschrift voor Oncologie, 2007, Vol.4, nr. 8, p. 376-378.

BOOG 2006-07 / MIRROR

Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.

M.J. Pepels, M. de Boer, P. Bult, J.A.A.M. van Dijck, C.H.M. van Deurzen, M.B.E. Menke-Pluymers, P.J. van Diest, G.F. Borm, and V.C.G. Tjan-Heijnen
Ann Surg, in press

Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location.

J.H.M.J. Vestjens, M. de Boer, P.J. van Diest, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, E.M.M. Adang, P. Bult, and V.C.G. Tjan-Heijnen.

Breast Cancer Res Treat, in press

Relevant impact of central pathology review on nodal classification, but not on the association of small nodal metastases with breast cancer outcome. Results from the Dutch MIRROR study.

J.H.M.J. Vestjens, M. de Boer, G.F. Borm, C.H.M. van Deurzen, P.J. van Diest, J.A.A.M. van Dijck, E.M.M. Adang, J.W.R. Nortier, E.J.T. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, and V.C.G. Tjan-Heijnen



Abstract PD06-04, poster presentation. San Antonio Breast Cancer Conference 2010, San Antonio, Texas, USA.

Cancer Res; 70(24 Suppl) Dec 15, 2010; PD06-04.

Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes.

M. de Boer, E.M.M. Adang, K. C. Van Dycke, J.A.A.M. van Dijck, G.F. Borm, C.H.M. van Deurzen, P.J. van Diest, P. Bult, A.R.T. Donders, V.C.G. Tjan-Heijnen.

*Abstract #614, poster presentation. ASCO Annual Meeting 2010, Chicago, Illinois, USA.
J Clin Oncol 28:15s, 2010.*

Micrometastases and isolated tumor cells in breast cancer are indeed associated with poorer outcome.

P.J. van Diest, M. de Boer, C.H.M. van Deurzen, V.C.G. Tjan-Heijnen.
J Clin Oncol 2010; 28(9):e140; author reply e141-2.

Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study.

M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C.Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen
*Abstract #CRA506, oral presentation, ASCO Annual Meeting 2009, Orlando, Florida, USA.
J Clin Oncol 27:18s, 2009.*

Isolated tumor cells in axillary lymph nodes of breast cancer patients: differential prognostic impact of single tumor cell(s) versus tumor cell clusters, and microanatomic location. New results from the Dutch MIRROR study.

P.J. van Diest, H. Schut, M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, E.M.M. Adang, P. Bult, and V.C.G. Tjan-Heijnen.

Abstract #306, poster discussion session. San Antonio Breast Cancer Conference 2009, San Antonio, Texas, USA.

Isolated Tumor Cells in Breast Cancer

Correspondence to the editor, N Engl J Med 361:1994-1996, November 12, 2009

Minimal lymph node involvement and outcome of breast cancer. The results of the Dutch MIRROR study. Tjan-Heijnen VC, de Boer M.

Discov Med. 2009 Oct;8(42):137-9.

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer

M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen.
N Engl J Med 361:653-63, August 13, 2009

Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists' group (BOOG).

M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen.
Abstract #23, oral presentation. San Antonio Breast Cancer Conference 2008, San Antonio, Texas, USA.

BOOG 2007-01 / ALLTO



Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers F, Schuehly U, Korde L, Azim H. A., Di Cosimo S, Tenglin R. C., Bodo Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M. J., Gelber R. D., De Azambuja E., Ignatiadis M

Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10065-10065

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E

J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy094

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

C F. Spraggs, LR Parham, L P Briley, L Warren, L S Williams, D Fraser, Z Jiang, Z Aziz, S Ahmed, G Demetrious, Z Tong, A O. Mehta, N Jackson, J Byrne, M Andersson, M Toi, L Harris, J Gralow, JA Zujewski, R Crescenzo, A Armour, E Perez, M Piccart

Pharmacogenomics J. 2018 May 22;18(3):480-486

Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial

Martel S, Lambertini M, Agbor-Tarh D, Ponde N, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A. C., Maurer C, Piccart-Gebhart M. J., Moreno-Aspitia A, Desmedt C, Di Cosimo S, De Azambuja E

Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10067-10067

Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)

M. Lambertini C. Campbell J. Bines L. Korde M.A. Izquierdo Delso D. Fumagalli K. Pritchard A. Wolff C. Jackisch I. Lang M. Untch I. Smith F.M. Boyle B. Xu C.H. Barrios J. Baselga A. Moreno-Aspitia M. Piccart R. Gelber E. De Azambuja

Ann Oncol. 2017 Sept 1 doi: 10.1093/annonc/mdx362.009

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Sonnenblick A., Agbor-Tarh D., Bradbury I., Di Cosimo S., Azim H. A., Fumagalli D., Sarp S., Wolff A. C., Andersson M., Kroep J., Cufer T., Simon S. D., Salman P., Toi M., Harris L., Gralow J., Keane M., Moreno-Aspitia A., Piccart-Gebhart M., de Azambuja E.

J Clin Oncol. 2017 May 1;35(13):1421-1429

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.

A Moreno-Aspitia, E McCormick Holmes, C Jackisch, E De Azambuja, F. M. Boyle, D W. Hillman,
J. of Clinical Oncology 35, no. 15_suppl (May 2017) 502-502.

Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial

Minetta C Liu₁, Brigitte Rack₂, Amylou C Dueck₄, David W Hillman₁, Michael B Campion₁, Monica M Reinholz₃, Kevin C Halling₁, Christos Sotiriou₅, Françoise Rothé₅, Marion Maetens₅, Ghizlane Rouas₅, Wolfgang Janni₆, Antonio C Wolff₇, Lyndsay N Harris₈, Julie R Gralow₉, Kathleen I Pritchard₁₀, Susan

Ellard¹², Nguyet A Le-Lindquist¹³, Frances Boyle¹⁴, Evandro De Azambuja⁵, Martine J Piccart-Gebhart⁵, Michail Ignatiadis⁵ and Edith A Perez¹¹.
SABCS 2014, publication number: P4-01-01

Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial

McCullough AE, Dell'Orto P, Reinholt MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrijetho S, Chen B, Lingle WL, Jackisch C, Perez EA, Piccart-Gebhart MJ, Viale G.
Cancer Res; 70(24 Suppl) Dec 15, 2010; P3-10-06

Adjuvant Lapatininb en/of Trastuzumab Treatment Optimization studie (ALTTO, BOOG 2007-01)

J.W.R.Nortier, NTvO juni 2009

The new generation of breast cancer clinical trials: the right drug for the right target].

De Azambuja E, Cardoso F, Meirman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M.
Bull Cancer. 2008 Mar;95(3):352-7. Review. French.

Jumping higher: is it still possible? The ALTTO trial challenge

G. Tomassello, E. de Azambuja, P. Dinh, N. Snoj and M. Piccart-Gebhart; *Expert Rev. Anticancer Ther.* 8(12), 1883-1890 (2008)

BOOG 2007-02 / INTENS

Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer

Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists'.
Eur J Cancer 2013 Oct;49(15):3102-10

Neoadjuvant chemotherapy and pathologic complete response in relation to clinical response, results from a phase III study (INTENS) of the Dutch breast cancer trialists' group (BOOG).

VCG Tjan-HeijnenA, BEPJ VriensA, B de VriesA, SM van GastelB, J WalsC, TJ SmildeD, LJC van WarmerdamE, HWM van LaarhovenF , DJ van SpronsenG, GF BormF
SABCs 2012

Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), toxicity results from a phase III study of the Dutch breast cancer trialists' group (BOOG).

Vriens BEPJ, Van de Vijver KKBT, Boetes C, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJC, van Laarhoven HWM, van Spronsen DJ, Borm GF, Tjan-Heijnen VCG.
Cancer Res; 71 (24 Suppl) Dec 15, 2011

Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch breast cancer trialists' group (BOOG).

Vriens BE, Van de Vijver KK, Boetes C, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, van Laarhoven HW, van Spronsen DJ, Borm GF, Tjan-Heijnen VCG.
Cancer Res; 70(24 Suppl) Dec 15, 2010;

BOOG 2008- 01 / 2-2-6 G-CSF

Primary Granulocyte Colony-Stimulating Factor for Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in patients with breast cancer at risk for febrile neutropenia

M.J. Aarts, F.P. Peters, C.M. Mandigers, M.W. Dercksen, J.M. Stouthard, J.W.R. Nortier, H.W. van Laarhoven, L.J. van Warmerdam, A.J. van de Wouw, E.M. Jacobs, V. Mattijsen, C.C. van der Rijt, T.J. Smilde, A.W. van der Velden, M. Temizkan, E. Batman, E.W. Muller, S.M. van Gastel, G.F. Borm, V.C. Tjan-Heijnen.

J Clin Oncol 2013; April 29, [Epub ahead of print]

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.

Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijsen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.

Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijsen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.

J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29

Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia.

Aarts MJ, Peters FP, Mandigers CM, Dercksen WM, Stouthard JM, Nortier JWR, van Laarhoven HWM, van Warmerdam LJ, van de Wouw YA, Jacobs EM, Mattijsen VE, van der Rijt CCD, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van der Vegt SG, van Gastel SM, Borm GF, Tjan-Heijnen VCG, (2012) (submitted)

Primary G-CSF prophylaxis during the First Two cycles only or Throughout All chemotherapy cycles in breast cancer patients at risk of Febrile Neutropenia: First results from a phase III trial of the Dutch Breast Cancer Trialists Group (BOOG)

M.J.B. Aarts, F.P.J. Peters, M.W. Dercksen, C. Mandigers, S. van Gastel, V.C.G. Tjan-Heijnen
Support Care Cancer 2010;18 (Suppl 3):S 09-078

Primary G-CSF prophylaxis during the First Two cycles only or Throughout All chemotherapy cycles in breast cancer patients at risk of Febrile Neutropenia: Final results from a phase III trial of the Dutch Breast Cancer Trialists Group (BOOG)

M.J.B. Aarts, F.P.J. Peters, M.W. Dercksen, C. Mandigers, J. Stouthard, J.W.R. Nortier, Y.J.L. Kamm, L.J.C. van Warmerdam, C.D. van der Rijt, S. van Gastel, M. Joore, A. Kessels, V.C.G. Tjan-Heijnen
Cancer Res; 2010;70(24) Suppl; P3-15-01

BOOG 2008-02 / A6181099 (SUTENT)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Barrios CH, Liu MC, Lee SC, Vanleemmen L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M.

Breast Cancer Res Treat. 2010 May;121(1):121-31. Epub 2010 Mar 26.

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

J. Crown, V. Dieras, E. Staroslawska, D. A. Yardley, N. Davidson, T. D. Bachelot, V. R. Tassell, X. Huang, K. A. Kern, G. Romieu;

J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1011)

BOOG 2008-03 / HAT

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S.

Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.

Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA-HAT) at progression as first-line treatment for patients with Her2 positive metastatic breast cancer: The HAT-Study

Jan C Drooger¹, Harm van Tinteren², Steffen M de Groot³, Albert J ten Tije⁴, Hiltje de Graaf⁵, Johanneke EA Portielje⁶, Agnes Jager¹, Aafke H Honkoop⁷, Sabine C Linn², Judith R Kroep⁸, Frans LG Erdkamp⁹, Paul Hamberg¹⁰, Joan B Heijns⁴, A Elise van Leeuwen-Stok¹¹ and Stefan Sleijfer¹.

SABCS 2014, publication number: P4-15-12

BOOG 2008-03/HAT-studie: Een gerandomiseerde fase II-studie bij patiënten met gemetastaseerde borstkanker met Her2/neu-overexpressie

J.Ph. van den Tol en S. Sleijfer;
NTvO, 2009, Vol.6 nr 8:365-66

BOOG 2009-01 / IRMA

Nog geen publicaties

BOOG 2009-02 / SNARB

Sentinel Node and Recurrent Breast Cancer (SNARB): Results of a Nationwide Registration Study

Maaskant AJG, Roumen RMH, Voogd AC, Pijpers R, Luiten EJT, Rutgers EJT, Nieuwenhuijzen GAP
Annals of Surgical Oncology (2012), DOI 10.1245/s10434-012-2625-7

Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure

F.Derkx, A.J.G. Maaskant-Braat, M.J.C. van der Sangen, G.A.P. Nieuwenhuijzen, L.V. van de Poll-Franse, R.M.H. Roumen, A.C. Voogd
Eur J Surg Oncol (2010), doi:10.1016/j.ejso.2010.05.009

Schildwachtklierprocedure bij recidief mammaarcinoom (SNARB); resultaten van een interim-analyse

Maaskant AJG, Bruijn de S, Roumen RMH, Nieuwenhuijzen GAP
Catharina-ziekenhuis, Eindhoven, afdeling Heelkunde
Abstract Chirurgendagen NVH 21-05-2010

Schildwachtklierprocedure: ook een mogelijkheid bij patiënten met een recidief van een mammaarcinoom

R.M.H. Roumen, G.P. Kuijt en I.H. Liem
Ned Tijdschr Geneesk. 2008;152:13-9

BOOG 2009-03 / DCIS

Patient-reported outcomes in ductal carcinoma in situ (DCIS): A systematic review. *European Journal of Cancer*, Accepted 7th October 2016. King MT, Winters Z, Butow P, Chua B, Saunders C, Spillane A, Mann GB, Olivotto I, Westenberg AH, Burnett P, Rutherford C.

BOOG 2009-04 / Male Breast cancer

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso F^{1,2}, Bartlett JMS^{3,4}, Slaets L⁵, van Deurzen CHM^{6,7}, van Leeuwen-Stok E⁷, Porter P^{8,9}, Linderholm B^{10,11}, Hedenfalk I¹², Schröder C^{7,13}, Martens J^{7,14}, Bayani J³, van Asperen C^{7,15}, Murray M¹⁶, Hudis C^{17,18}, Middleton L¹⁹, Vermeij J²⁰, Punie K²¹, Fraser J²², Nowaczkyk M²³, Rubio IT²⁴, Aebi S²⁵, Kelly C²⁶, Ruddy KJ²⁷, Winer E²⁸, Nilsson C^{29,30}, Dal Lago L³¹, Korde L³², Benstead K³³, Bogler O³⁴, Goulioti T³⁵, Peric A⁵, Litière S⁵, Aalders KC⁵, Poncet C⁵, Tryfonidis K⁵, Giordano SH³⁶.

Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Vermeulen MA¹, Slaets L², Cardoso F³, Giordano SH⁴, Tryfonidis K², van Diest PJ¹, Dijkstra NH⁵, Schröder CP⁶, van Asperen CJ⁷, Linderholm B⁸, Benstead K⁹, Foekens R¹⁰, Martens JWM¹¹, Bartlett JMS¹², van Deurzen CHM¹³.

Eur J Cancer. 2017 Sep;82:219-227. doi: 10.1016/j.ejca.2017.01.034. Epub 2017 Mar 11.

Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Doebar SC¹, Slaets L², Cardoso F³, Giordano SH⁴, Bartlett JM⁵, Tryfonidis K², Dijkstra NH⁶, Schröder CP^{7,6}, van Asperen CJ^{8,6}, Linderholm B⁹, Benstead K¹⁰, Dinjens WN¹, van Marion R¹, van Diest PJ¹¹, Martens JW^{12,6}, van Deurzen CH^{1,6}.

Mod Pathol. 2017 Apr;30(4):509-518.

Performance of BRCA1/2 mutation prediction models in male breast cancer patients.

Moghadasi S, Grudeken V, Janssen LAM, Dijkstra NH, Rodríguez-Girondo M, van Zelst-Stams WAG, Oosterwijk JC, Ausems MGEM, Oldenburg RA, Adank MA, Blom EW, Ruijs MWG, van Os TAM, van Deurzen CHM, Martens JWM, Schroder CP, Wijnen JT, Vreeswijk MPG, van Asperen CJ.

Clin Genet. 2018 Jan;93(1):52-59. doi: 10.1111/cge.13065. Epub 2017 Sep 25.

Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program

F. Cardoso, J. Bartlett, L. Slaets, C. van Deurzen, E. van Leeuwen-Stok, P. Porter, B. Linderholm, I. Hedenfalk, C. Schröder, J. Martens, J. Bayani, C. van Asperen, M. Murray, C. Hudis, L. Middleton, J. Vermeij, S. Peeters, J. Fraser, M. Nowaczkyk, I.T. Rubio, S. Aebi, C. Kelly, K. Ruddy, E. Winer, C. Nilsson, L. Dal Lago, L. Korde, K. Benstead, D. van den Weyngaert, O. Bogler, Th. Goulioti, N. Dif, C. Messina, K. Tryfonidis, J. Bogaerts and S. Giordano
SABCS 2014 - Abstract no. S6-05

Male breast cancer in the Netherlands: uptake and outcome of BRCA testing

Results of study the Dutch Breast Cancer Research Group (BOOG 2009-04) in collaboration with the EORTC 10085 study.

CJ van Asperen, N Dijkstra, PJM van Hees, WAG van Zelst-Stams, JC Oosterwijk, MGE Ausems, RA Oldenburg, MA Adank, EW Blom, M Ruijs, TAM van Os, LAM Janssen, CHM van Deurzen, S Roshani, JWM Martens, CP Schroder

European Society Human Genetics (ESHG 2014, Milaan) – Abstract no. P12.085-S.

BOOG 2009-05 / BOLERO-2

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.

JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.1279. [Epub ahead of print]

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J.
J Clin Oncol. 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. Epub 2015 Oct 26.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study.

Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimy M, Taran T, Sahmoud T, Piccart M.
Eur J Cancer. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. Epub 2013 Jun 1.

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI.

J Natl Cancer Inst. 2013 May 1;105(9):654-63. doi: 10.1093/jnci/djt026. Epub 2013 Feb 19.

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.

Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Baulx H, Taran T, Sahmoud T, Noguchi S.

Cancer. 2013 May 15;119(10):1908-15. doi: 10.1002/cncr.28010. Epub 2013 Mar 15.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.

Breast Cancer. 2013 Feb 13. [Epub ahead of print]

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN.

N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial

Baselga J, Campone M, Sahmoud T, Piccart M, Burris H, Rudo H, Noguchi S, Gnant M, Mukhopadhyay P, Hortobagyi G

Abstract ESMO 2011

Presentatie ECCO 2011

BOOG 2010-01 / NEO-ZOTAC

Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is 1 associated with better tumor control in breast cancer patients treated with neoadjuvant 2 chemotherapy with or without zoledronic acid.

De Groot F, et al. *Submitted 2018*

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies. Vriens BE, Keymeulen KB, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJ, Heuts EM, Tjan-Heijnen VC, The Dutch Breast Cancer Research Group Boog. *Oncotarget*. 2017;8(28):46557-64

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

J.R. Kroep, A. Charehbili, R.E. Coleman, R.L. Aft, Y. Hasegawa, M.C. Winter, K. Weilbaecher, K. Akazawa, S. Hinsley, H. Putter, G.J. Liefers, J.W.R. Nortier, N. Kohno
European Journal of Cancer 54 (2016) 57-63

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2016 Jan 6;18(1):3

Vitamin D (25-OH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).

Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenborg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Breast. 2016 Feb;25:69-74.

Serum vit D levels and response to molecular subtypes in breast cancer.

Kroep J, Charehbili A, Hamdy N.
Breast. 2016 Jun;27:186.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.
Mol Cancer Ther. 2015 Mar;14(3):821-7.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van BA, van Laarhoven HW, Meershoek-Klein KE, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR
Breast Cancer Res Treat 2015;149:461-466.

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.

Dekker TJ, Charehbili A, Smit VT, ten Dijke P, Kranenborg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR.
Mol Oncol. 2015 Jun;9(6):1120-8

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2016 Jan 6;18(1):3.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.

Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JW, Kohno N.

Eur J Cancer. 2015 Dec 23;54:57-63.

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.

Charehbili A, de Groot S, van der Straaten T, Swen JJ, Pijl H, Gelderblom H, van de Velde CJH, Nortier J, Guchelaar HJ, Kroep JR.

Pharmacogenomics. 2015 Jul;16(11):1-10.

Vitamin D (25-OH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenborg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJH, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).

Breast. 2015 Nov 21 [Epub ahead of print]

Op het SABCS had Stefanie de Groot een poster:

Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01). de Groot S et al. SABCS 2016, publication number P3-07-54.

Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)

S de Groot¹, A Charehbili¹, L GM Janssen¹, E M Dijkgraaf¹, V THBM Smit¹, L W Kessels², A van Bochove³, H WM van Laarhoven⁴, E Meershoek-Klein Kranenborg¹, A E van Leeuwen-Stok⁵, G J Liefers¹, C JH van de Velde¹, J WR Nortier¹, J JM van der Hoeven¹, H Pijl¹ and J R Kroep¹.

SABCS 2014, publication number: P3-06-50

Sentinel node procedure before or after neoadjuvant chemotherapy in clinically node negative or positive patients; results from 3 phase III studies of the Dutch breast cancer trialists' group (BOOG)

Vivianne C Tjan-Heijnen¹, Birgitte E Vriens¹, Maureen J Aarts¹, Judith R Kroep², Cock J van de Velde², Gerrit-Jan Liefers², Ayoub

Charehbili², Petronella G Peer³ and Maaike de Boer¹.

Abstract SABCS, publication number P2-01-03

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).

Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenborg E, Hamdy NA, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven HW, Vriens B, Wasser MN, van Leeuwen-Stok AE, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR. *Annals of Oncology. 2014 May; 25(5):998-1004*

Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomized trials.

Colemen RE et al.

2013 San Antonio Breast Cancer Symposium. Abstract S4-07.

Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer. Charehbili A et al. European Cancer Congress 2013- Oral presentation, Abstract No: 1858

NEO-ZOTAC: Efficacy of NEOadjuvant chemotherapy (TAC) with or without Zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC) A Dutch Breast Cancer Trialists' Groups (BOOG) study.

Charehbili A, van de Ven S, Liefers GJ, Smit VTHBM, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven H, Vriens B, Wasser MN, Hamdy NAT, Meershoek-Klein Kranenborg EM, van Leeuwen-Stok AE, van de Velde CJH, Nortier JWR, Kroep JR. ASCO Annual Meeting 2013 - Abstract No: 1028.

NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without Zoledronic acid for patients with HER2-negative large resectable or locally advanced breast cancer

van de Ven S, Charehbili A, Liefers GJ, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven H, Vriens B, Smit VT, Wasser, Meershoek-Klein Kranenborg E, van Leeuwen-Stok AE, van de Velde CJH, Nortier JWR, Kroep JR
Abstract SABCS 2012 PD07-06

NEO-ZOTAC: A Phase III Randomized Trial with Neoadjuvant Chemotherapy (TAC) with or without Zoledronic Acid for Patients with HER2-Negative Large Resectable or Locally Advanced Breast Cancer.

Abstract SABCS 2011, Program Number: OT1-01-04

Een nieuwe rol voor bisfosfonaten in de behandeling van het mammaarcinoom; het anti-tumoreffect?

Van de Ven S, Kroep JR, Hamdy NAT, Sleeboom AP, Nortier JWR:
Ned Tijdschr Geneesk. 2010;154:A1951

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJH, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.
Mol Cancer Ther. 2015 Mar;14(3):821-7.

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.

Dekker TJ, Charehbili A, Smit VT, Ten Dijke P, Meershoek-Klein Kranenborg E, van de Velde CJH, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR.
Mol Oncol. 2015 Jun;9(6):1120-8.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).

de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenborg E, van Leeuwen-Stok AE, van de Velde CJH, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR.
Breast Cancer Res Treat. 2015 Jan;149(2):461-6.

BOOG 2010-02 / STOP & GO

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).

Claessens AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, van Druten E, van Warmerdam LJC, van der Sangen MJC, Tjan-Heijnen VCG, Erdkamp FLG Dutch Breast Cancer Research Group (BOOG).

Breast Cancer Res Treat. 2018 Nov;172(2):413-423. doi: 10.1007/s10549-018-4906-8. Epub 2018 Aug 18.

Resultaten zijn op ESMO 2017 gepresenteerd door Anouk Claessens, promovenda (Poster 246-PD) gevuld door een discussie sessie geleid door Alessandra Gennari (Galliera Hospital, Genua, Italië)

BOOG 2010-03 / RAPCHEM

Radiotherapy After Primary CHEMotherapy (RAPCHEM): a prospective registration study

L. Boersma, P. Elkhuzien, R. Houben, E. van Leeuwen, S. Linn, L. de Munck, R. Pijnappel, L. Strobbe, T. van Dalen, J. Verloop, A. Voogd, J. Wesseling, P. Poortmans.

Abstract EBCC 2016

BOOG 2010-04 / D-care

De primaire analyse is op ASCO 2018 gepresenteerd

Coleman R, et al. Presented at: American Society of Clinical Oncology; June 1-5, 2018; Chicago, IL. USA.

BOOG 2010-05 / SUBMIT

SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation

Jetske Ruiterkamp¹, Adri C Voogd², Vivianne CG Tjan-Heijnen³, Koop Bosscha⁴, Yvette M van der Linden⁵, Emiel JTh Rutgers⁶, Epie Boven⁷, Maurice JC van der Sangen⁸, Miranda F Ernst^{39*} and In collaboration with Dutch Breast Cancer Trialists' Group (BOOG)

BMC Surgery 2012, 12:5 doi:10.1186/1471-2482-12-5

The role of surgery in metastatic breast cancer

47 Suppl 3:S6-22. doi: 10.1016/S0959-8049(11)70142-3.

Ruiterkamp J, Ernst MF.

Eur J Cancer. 2011 Sep

Presence of symptoms and timing of surgery do not affect the prognosis of patients with primary metastatic breast cancer.

Ruiterkamp J, Voogd AC, Bosscha K, Roukema JA, Nieuwenhuijzen GA, Tjan-Heijnen VC, Ernst MF.

Eur J Surg Oncol. 2011 Oct;37(10):883-9. doi: 10.1016/j.ejso.2011.07.004. Epub 2011 Aug 16.

Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nation wide population-based study in The Netherlands.

Ruiterkamp J, Ernst MF, de Munck L, van der Heiden-van der Loo M, Bastiaannet E, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC.

Breast Cancer Res Treat. 2011 Jul;128(2):495-503. doi: 10.1007/s10549-011-1349-x. Epub 2011 Jan 15.

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF.

Breast Cancer Res Treat. 2010 Feb;120(1):9-16. doi: 10.1007/s10549-009-0670-0. Epub 2009 Dec 13.

Review.

Jetske Ruiterkamp Thesis 'Surgery in metastatic breast cancer'

BOOG 2011-02 APHINITY

Adjuvant, Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; *N Engl J Med.* 2017 Jul 13;377(2):122-131

Presentatie van de eerste analyse van de APHINITY studie heeft op de ASCO 2017 plaatsgevonden
J Clin Oncol 35, 2017 (suppl; abstr LBA500)

BOOG 2012-01 BALLET

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29

Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)

Guy Jerusalem¹, Gabriella Mariani², Eva M Ciruelos³, Miguel Martin⁴, Vivianne CG Tjan-Heijnen⁵, Patrick Neven⁶, Joaquin Gavila Gregori⁷, Andrea Michelotti⁸, Filippo Montemurro⁹, Istvan Lang¹⁰, Josef Mardiak¹¹, Bjoem Naume¹², Maura Camozzi¹³, Katia Lorizzo¹³, Dariusz Brenski¹³ and Pierfranco Conte¹⁴. ¹CHU Sart Tilman Liege and Liege University, Liege, Belgium; ²Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy; ³University Hospital 12 de Octubre, Madrid, Spain; ⁴Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁵Maastricht University Medical Centre, Maastricht, Netherlands; ⁶KU Leuven and University Hospital Leuven, Leuven, Belgium; ⁷Fundacion Instituto Valenciano de Oncologia, Valencia, Spain; ⁸Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Pisa, Italy; ⁹Fondazione del Piemonte per l'Oncologia, Institute of Candiolo Cancer Center (IRCCs), Candiolo (Torino), Italy; ¹⁰National Institute of Oncology, Budapest, Hungary; ¹¹National Cancer Institute, Bratislava, Slovakia (Slovak Republic); ¹²Oslo University Hospital and Norwa and K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway; ¹³Novartis Farma S.p.A., Origgio/VA, Italy and ¹⁴Istituto Oncologico Veneto IRCCS and Università di Padova, Padova, Italy.
SABCS 2014, publication number: P5-19-02

BOOG 2012-02 / SafeHer

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

J. Gligorov , B. Ataseven , M. Verrill , M. De Laurentiis , K.H. Jung e, H.A. Azim , N. Al-Sakaff , S. Lauer , M. Shing i , X. Pivot on behalf of the SafeHer Study Group.

EJC 82(2017)237-246

SafeHer Phase III study primary analysis: Safety of subcutaneous trastuzumab plus chemotherapy for early breast cancer

EBCC 2016 abstract number: 326

SafeHer Phase III study primary analysis: Safety of subcutaneous trastuzumab plus chemotherapy for early breast cancer

J. Gligorov⁽¹⁾, B. Ataseven⁽²⁾, M. Verrill⁽³⁾, M. De Laurentiis⁽⁴⁾, K.H. Jung⁽⁵⁾, H.A. Azim⁽⁶⁾, N. Al-Sakaff⁽⁷⁾, S. Lauer⁽⁸⁾, M. Shing⁽⁹⁾, X. Pivot⁽¹⁰⁾

EBCC 2016 poster presentation 343

Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

Poster presented at the European Cancer Congress 2015, September 25–29 2015, Vienna, Austria

BOOG 2012-03 / TRAIN-2

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicenter, open-label, randomized, phase 3 trial.

Van Ramshorst MS, van der Voort A, van Werkhoven ED, Manjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MJTFD, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Lancet Oncol 2018; 19: 1543-1698

Fine-tuning chemotherapy in the era of dual HER2 targeting

Editorial Lancet Oncol 2018

A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer: the TRAIN-2 study (BOOG 2012-03)

Van Ramshorst MS, van Werkhoven ED, Manjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, Wesseling J, Vrancken Peeters MJTFD, Linn SC, Sonke GS; ASCO 2017 abstract number 507

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

Van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). *Breast. 2016;29:153-9.*

Safety analyses of the first 110 patients treated with dual HER2-blockade in the TRAIN-2 study

Mette S van Ramshorst^{1*}, Erik van Werkhoven², Aafke H Honkoop³, Vincent O Dezentjé⁴, Irma M Oving⁵, Ingrid AM Mandjes², Inge Kemper¹, Jacqueline M Stouthard¹, Sjoerd Rodenhuis¹, Sabine C Linn¹, Gabe S Sonke^{1*}

EBCC 2016 abstract number 343

BOOG 2013-02 / PROS MALE BC

Poster presentatie in San Antonio van het internationale male BC consortium (met John Bartlett als PI) over de prognostische waarde van bestaande gen expressie signatures in male BC.

BOOG 2013-03 / PERNETTA

Huober J, et al. Presented at: European Society for Medical Oncology (ESMO) Congress, Munich, Germany, October 19-23, 2018.

BOOG 2013-04 / DIRECT

Dietary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013-04).

S. de Groot¹, R.T. Lugtenberg¹, M.J.P. Welters¹, I. Ehsan¹, M.P.G. Vreeswijk¹, D. Cohen¹, V.T.H.B.M. Smit¹, H. de Graaf², J. B. Heijns³, J.E.A. Portielje^{1,4}, A.J. van de Wouw⁵, A.L.T. Imholz⁶, L.W. Kessels⁶, S. Vrijaldenhoven⁷, A. Baars⁸, E. Meershoek-Klein Kranenbarg¹, M. Duijm-de Carpenter¹, H. Putter¹, V.D. Longo⁹, J.J.M. van der Hoeven¹, J.W.R. Nortier¹, H. Pijl¹, J.R. Kroep¹ on behalf of the Dutch Breast Cancer Research Group (BOOG)¹⁰
SABCS Poster presentation(P1-15-20)

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.

de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR.
BMC Cancer. 2015 Oct 5;15:652.

BOOG 2013-06 / BIOMARKER EVEROLIMUS

PI3K-Akt-mTOR pathway analysis to obtain further insight in the efficacy of everolimus in combination with exemestane in metastatic, ER-positive breast cancer: A Dutch breast cancer research group (BOOG) study Ninja T Kruger¹, Karin Beelen², Connie R Jimenez¹, Maurice PHM Jansen³, Stefan Sleijfer³, Sabine C Linn² and Epie Boven^{1..}
SABCS 2014, publication number: OT1-1-02

De Everolimus Biomarker Studie: analyse van de PI3K-Akt-mTOR route om meer inzicht te verkrijgen in de effectiviteit van everolimus in combinatie met exemestaan bij gemitastaseerd mammaacarcinoom - Een studie van de Borstkanker Onderzoek Groep (BOOG) Nederland
Kruger DT, Linn SC, Beelen K, Sleijfer S, Jansen MPH, Jimenez CR, Boven E.
Ned Tijdschr Oncol 2014;11:250-254

Biomarker Study Everolimus, een studie van de Borstkanker Onderzoek Groep Nederland

Kruger DT, Beelen K, Sleijfer S, Jansen MPH, Jimenez CR, Linn SC, Boven E.
Kanker Breed 2014;6:23-25

BOOG 2014-01 / MONALEESA-2

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.

Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA. <<https://www.ncbi.nlm.nih.gov/pubmed/29058175>> *Breast Cancer Res Treat.* 2018 Feb;167(3):659-669

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliogy M, Germa C, O'Shaughnessy J.
Ann Oncol. 2018 Jul 1;29(7):1541-1547

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial

O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.
Breast Cancer Res Treat. 2018 Feb;168(1):127-134

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial

Joyce O'Shaughnessy, Katarina Petrakova, Gabe S. Sonke, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Joseph T. Beck, Deborah Lindquist, Farida Souami, Shoubhik Mondal, Caroline Germa¹, Gabriel N. Hortobagyi
Breast Cancer Research and Treatment, 18 September 2017

Poster presented at SABCS, December 2016, San Antonio.

First-line Ribociclib + Letrozole in Patients With De Novo HR+, HER2– Advanced Breast Cancer: A Subgroup Analysis of the MONALEESA-2 Trial. Publication number P4-22-05.
Joyce O'Shaughnessy, Katarina Petrakova, Gabe S. Sonke, Fabrice André, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Deborah Lindquist, Farida Souami, Xiaodong Li, Caroline Germa, Samit Hirawat, Gabriel N. Hortobagyi.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.

N Engl J Med. 2016 Oct 7.

BOOG 2014-03 / OLYMPIA

OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)

Mark Robson¹, Andrew Tutt², Judith Balmaña^{3, 12}, Bella Kaufman⁴, Judy Garber⁵, Charles Geyer⁶, James Ford⁷, Priyanka Sharma⁸, Mary Stuart⁹, Helen Mann⁹ and Peter A Fasching^{10, 11}.
SABCS, publication number: OT1-1-04

BOOG 2014-04 / LORD

Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study

Lotte E. Elshof a,b,c, Konstantinos Tryfonidis d, Leen Slaets e, A. Elise van Leeuwen-Stok f, Victoria P. Skinner a, Nicolas Dif g, Ruud M. Pijnappel h, Nina Bijker i, Emiel J.Th. Rutgers a, Jelle Wesseling b,j,↑
European Journal of Cancer (2015) 51, 1497–1510

The LORD trial: A randomized, non-inferiority trial, between active surveillance versus standard treatment in patients with low risk ductal carcinoma in situ

Lotte E Elshof, Konstantinos Tryfonidis, Leen Slaets, A Elise van Leeuwen-Stok, Nicolas Dif, Victoria P Skinner, Claudette E Loo, Gonnieke Warnars, Eveline Bleiker, Ruud M Pijnappel, Nina Bijker⁵, Emiel JTh Rutgers and Jelle Wesseling,

Abstract SABCS 2014, Program Number: OT3-6-01

BOOG 2014-05 / INFLAME

Immune cell type fractions and gene expression in inflammatory breast cancer

Bense R, de Vries EGE, Fehrmann R, Schröder CP. Oral poster presentation by C.P. Schröder on July 10, 2016.

5th International Inflammatory Breast Cancer Conference, Harvard Medical School, Boston, U.S.A.



BOOG 2015-01 / MONARCH-3

Goetz MP, et al. Presented at: American Society of Clinical Oncology, June 1-5, 2018; Chicago, IL. USA.

BOOG 2015-02 / MONALEESA-3

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G.

J Clin Oncol. 2018 Aug 20;36(24):2465-2472

BOOG 2017-03 / SONIA


Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial. BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.

van Ommen-Nijhof A1, Konings IR2, van Zeijl CJJ2, Uyl-de Groot CA3, van der Noort V1, Jager A4, Sonke GS5; SONIA study steering committee.

BOOG 2018-01 / TRAIN-3

Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study.

van der Voort A, van Ramshorst MS, Dezentjé VO, van der Steeg WA, Winter-Warnars GAO, Schipper RJ, Scholten AN, Wesseling J, van Werkhoven ED, van Duijnoven F, Vrancken Peeters MJTFD, Sonke GS; On behalf of the Dutch Breast Cancer Research Group (BOOG)
SABCS 2018 poster presentation abstract number 1079



Patientenparticipatie

Patients' perceptions on breast cancer clinical trials

S. Tax., J.E. Elberse, C.A.C.M. Pittens, A.E. van Leeuwen-Stok, M. Schrieks, J.E.W. Broerse

Abstract ECCO 2013

How breast cancer patients value partaking in non-commercial clinical trials

C.A.C.M. Pittens, J.E. Elberse, A.E. Van Leeuwen-Stok, M. Jonker, J.E.W. Broerse

Submitted European Journal of Cancer Care, 2013

Patient involvement in breast cancer clinical trials: what do patients and professionals want?

C.A.C.M. Pittens, J.E. Elberse, A. E. Van Leeuwen-Stok, S. Tax, J.E.W. Broerse

Submitted Health Expectations, 2013

Wat wil de patient als het om onderzoek gaat? Interview met E. van der Wall,

Medische Oncologie dec 2012

Active Patient Involvement in Breast Cancer Clinical Trials, C.A.C.M. Pittens,

Presentatie 6th Clinical Forum Congress, 8-10 oktober 2012

Patients' Perceptions On Breast Cancer Clinical Trials

C.A.C.M. Pittens, J.E. Elberse, S. Tax, A.E. van Leeuwen-Stok, M. Schrieks, M. Jonker, J.E.W. Broerse

Abstract EBCC-8, 2012